Hydrodilatation With Hypertonic Dextrose Solution Injection After Intra-articular Steroid Injection for Frozen Shoulder
Launched by TRI-SERVICE GENERAL HOSPITAL · Dec 3, 2023
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new treatment approach for frozen shoulder, a condition that causes pain and stiffness in the shoulder joint. The researchers want to see if a combination of a corticosteroid injection, followed by an injection of a special sugar solution (hypertonic dextrose), works better than a saline (salt water) injection for relieving symptoms and improving shoulder movement.
To participate in the trial, individuals must have been diagnosed with frozen shoulder for more than three months and have significant limitations in shoulder movement. However, certain conditions may exclude someone from participating, such as having a severe shoulder injury or certain medical issues like uncontrolled diabetes or a history of cancer. The trial is not yet recruiting participants, but if you meet the criteria, you could help researchers learn more about effective treatments for frozen shoulder. Participants will receive injections and will be monitored to see how well the treatments work.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The diagnosis of frozen shoulder is determined by physicians through an evaluation of the patient's medical history, physical examination, and assessment of X-ray and ultrasound reports.
- • 2. The duration of symptoms should be more than 3 months.
- • 3. There should be a decrease of at least 30 degrees in a minimum of two shoulder joint angles (shoulder flexion, abduction, and external rotation) compared to the corresponding angles on the healthy side.
- Exclusion Criteria:
- • 1. Ultrasound examination of the shoulder muscles must not reveal a complete tear or massive tear of the rotator cuff tendon or evidence of calcific tendinitis.
- • 2. Presence of systemic rheumatic disease.
- • 3. History of previous shoulder fracture or undergoing surgical intervention.
- • 4. Receipt of shoulder joint injections within the last 3 months.
- • 5. Acute cervical nerve root compression.
- • 6. Current status of pregnancy or breastfeeding.
- • 7. Poorly controlled diabetes (since intravenous glucose injection may cause temporary blood sugar elevation).
- • 8. Patients with a history of cancer.
About Tri Service General Hospital
The Tri-Service General Hospital (TSGH) is a leading medical institution in Taiwan, dedicated to advancing healthcare through innovative clinical research and comprehensive patient care. As a prominent military hospital, TSGH integrates cutting-edge medical practices with rigorous scientific inquiry, fostering a collaborative environment for healthcare professionals and researchers. The hospital is committed to enhancing treatment outcomes and improving public health by conducting a diverse range of clinical trials across various medical specialties, ensuring adherence to the highest ethical standards and regulatory guidelines. Through its research initiatives, TSGH aims to contribute significantly to the global medical community and the advancement of evidence-based medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported